Rigel Pharmaceuticals (RIGL) plummets before the bell after adverse side effects were observed...

|About: Rigel Pharmaceuticals, Inc. (RIGL)|By:, SA News Editor

Rigel Pharmaceuticals (RIGL) plummets before the bell after adverse side effects were observed in a late-stage clinical trial of AstraZeneca's (AZN) rheumatoid arthritis drug fostamatinib. It also appears the drug may be inferior to AbbVie's Humira in terms of efficacy. The drug is licensed from Rigel whose shares are -35% premarket on heavy volume.